FR07C0046I2 - Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b - Google Patents

Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b

Info

Publication number
FR07C0046I2
FR07C0046I2 FR07C0046C FR07C0046C FR07C0046I2 FR 07C0046 I2 FR07C0046 I2 FR 07C0046I2 FR 07C0046 C FR07C0046 C FR 07C0046C FR 07C0046 C FR07C0046 C FR 07C0046C FR 07C0046 I2 FR07C0046 I2 FR 07C0046I2
Authority
FR
France
Prior art keywords
desoxy
nucleosides
hepatitis
beta
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR07C0046C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idenix Cayman Ltd
Original Assignee
Idenix Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26791121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR07C0046(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idenix Cayman Ltd filed Critical Idenix Cayman Ltd
Publication of FR07C0046I1 publication Critical patent/FR07C0046I1/fr
Application granted granted Critical
Publication of FR07C0046I2 publication Critical patent/FR07C0046I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
FR07C0046C 1998-08-10 2007-09-21 Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b Active FR07C0046I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9611098P 1998-08-10 1998-08-10
US13135299P 1999-04-28 1999-04-28
PCT/US1999/018149 WO2000009531A2 (en) 1998-08-10 1999-08-10 β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B

Publications (2)

Publication Number Publication Date
FR07C0046I1 FR07C0046I1 (enrdf_load_stackoverflow) 2007-10-26
FR07C0046I2 true FR07C0046I2 (fr) 2008-05-09

Family

ID=26791121

Family Applications (1)

Application Number Title Priority Date Filing Date
FR07C0046C Active FR07C0046I2 (fr) 1998-08-10 2007-09-21 Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b

Country Status (21)

Country Link
US (5) US6395716B1 (enrdf_load_stackoverflow)
EP (2) EP1104436B1 (enrdf_load_stackoverflow)
JP (2) JP4294870B2 (enrdf_load_stackoverflow)
KR (4) KR100702230B1 (enrdf_load_stackoverflow)
CN (3) CN100482236C (enrdf_load_stackoverflow)
AT (1) ATE313550T1 (enrdf_load_stackoverflow)
AU (1) AU5475799A (enrdf_load_stackoverflow)
BR (1) BRPI9912896B8 (enrdf_load_stackoverflow)
CA (1) CA2340156C (enrdf_load_stackoverflow)
CY (2) CY2007017I2 (enrdf_load_stackoverflow)
DE (2) DE69929060T2 (enrdf_load_stackoverflow)
DK (3) DK1104436T3 (enrdf_load_stackoverflow)
ES (3) ES2531928T3 (enrdf_load_stackoverflow)
FR (1) FR07C0046I2 (enrdf_load_stackoverflow)
LU (1) LU91348I2 (enrdf_load_stackoverflow)
MX (1) MXPA01001507A (enrdf_load_stackoverflow)
NL (1) NL300286I2 (enrdf_load_stackoverflow)
PT (2) PT2415776T (enrdf_load_stackoverflow)
RU (1) RU2424016C2 (enrdf_load_stackoverflow)
SG (1) SG132498A1 (enrdf_load_stackoverflow)
WO (1) WO2000009531A2 (enrdf_load_stackoverflow)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040164A1 (en) * 1995-06-07 1996-12-19 Emory University Nucleosides with anti-hepatitis b virus activity
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CA2340156C (en) * 1998-08-10 2007-10-23 Novirio Pharmaceuticals Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
AU784374C (en) * 1999-11-12 2007-06-28 Pharmasset Inc Synthesis of 2'-deoxy-L-nucleosides
EP1600451A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-l-nucleosides
HK1048771A1 (zh) * 2000-02-29 2003-04-17 Bristol-Myers Squibb Co. 低剂量艾替开韦制剂及其应用
AU2001245575A1 (en) * 2000-03-09 2001-09-17 Videoshare, Inc. Sharing a streaming video
US6822089B1 (en) * 2000-03-29 2004-11-23 Isis Pharmaceuticals, Inc. Preparation of deoxynucleosides
DE60136620D1 (de) * 2000-04-13 2009-01-02 Pharmasset Inc 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA007867B1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
US6596700B2 (en) * 2000-05-26 2003-07-22 Idenix Pharmaceuticals Inc. Methods of treating hepatitis delta virus infection with β-L-2'-deoxy-nucleosides
US6787526B1 (en) * 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
MY141594A (en) * 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2002044194A1 (fr) * 2000-11-29 2002-06-06 Mitsui Chemicals, Inc. Derives d'acide l-nucleique et procedes de synthese correspondants
CN101250208B (zh) * 2000-11-29 2012-06-20 三井化学株式会社 L-核酸衍生物及其合成方法
US7211570B2 (en) 2001-12-20 2007-05-01 Pharmasset, Inc. Treatment of EBV and KHSV infection
WO2003055896A2 (en) * 2001-12-21 2003-07-10 Micrologix Biotech Inc. Anti-viral 7-deaza l-nucleosides
US7285658B2 (en) * 2002-02-28 2007-10-23 Biota, Inc. Nucleotide mimics and their prodrugs
JP2005533870A (ja) * 2002-06-27 2005-11-10 メディヴィル・アクチボラグ アバカビールおよびアロブジンの相乗的相互作用
CN100348607C (zh) 2002-06-28 2007-11-14 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒科病毒感染的2’和3’－核苷前药
MXPA04012802A (es) * 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
RS114104A (en) 2002-06-28 2007-02-05 Idenix (Cayman) Limited, 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
PT1572095E (pt) 2002-09-13 2015-10-13 Novartis Ag Β-l-2'-desoxinucleósidos para tratamento de estirpes resistentes de vhb
US7148349B2 (en) * 2002-10-31 2006-12-12 Metabasis Therapeutics, Inc. Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
CN101415719A (zh) 2003-03-20 2009-04-22 微生物化学及药品有限公司 生产2’-脱氧-β-L-核苷的方法
CN1812995A (zh) * 2003-04-28 2006-08-02 艾登尼科斯（开曼）有限公司 工业化规模的核苷合成
WO2004096197A2 (en) * 2003-05-02 2004-11-11 Universita Degli Studi Di Cagliari 5-aza-7-deazapurine nucleosides for treating flaviviridae
SI2604620T2 (sl) 2003-05-30 2024-10-30 Gilead Pharmasset Llc Modificirani fluorirani nukleozidni analogi
MXPA06000162A (es) * 2003-06-30 2006-03-21 Idenix Cayman Ltd Sintesis de ?-l-2-desoxinucleosidos.
CN1315863C (zh) * 2003-12-12 2007-05-16 河南省科学院质量检验与分析测试研究中心 β－L－2'－脱氧－核苷衍生物、其合成方法及其药物用途
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
JP5001842B2 (ja) 2004-09-14 2012-08-15 ギリアド ファーマセット エルエルシー ２’−フルオロ−２’−アルキル−置換又は他の置換されていてもよいリボフラノシルピリミジン類及びプリン類並びにそれらの誘導体の製造
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
EP1976382B1 (en) * 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
ES2543840T3 (es) 2006-04-11 2015-08-24 Novartis Ag Inhibidores espirocíclicos del VHC/VIH y sus usos
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090082306A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telbivudine
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
TW201026716A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside analogs
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
JP5779799B2 (ja) * 2009-11-16 2015-09-16 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド ２’−フルオロ−６’−メチレン炭素環ヌクレオシド類、及びウイルス感染の治療法
NZ603232A (en) 2010-03-31 2015-02-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
AU2011311880B2 (en) 2010-10-08 2014-07-24 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
CN102649788B (zh) * 2011-02-28 2015-03-25 四川大学 β-L-2’-脱氧-胸腺嘧啶核苷衍生物及其制备方法和用途
PE20141056A1 (es) 2011-09-16 2014-09-05 Gilead Pharmasset Llc Metodos para el tratamiento de vhc
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
HRP20200138T1 (hr) 2013-01-31 2020-08-21 Gilead Pharmasset Llc Kombinirana formulacija dva antivirusna spoja
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
WO2019139919A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
CN110680806A (zh) * 2018-07-04 2020-01-14 郑州泰丰制药有限公司 一种替比夫定颗粒的制备方法
CN108570078A (zh) * 2018-07-18 2018-09-25 荆门医药工业技术研究院 一种制备1-O-乙酰基-2,3,5-三-O-苯甲酰基-β-D-呋喃核糖的方法
CN114133398B (zh) * 2021-12-31 2022-11-22 中南民族大学 氨基酸取代的阿昔洛韦类三环核苷衍生物及其合成方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB875971A (en) 1959-01-14 1961-08-30 Hoffmann La Roche A process for the manufacture of uridine and thymidine derivatives and novel compounds concerned therein
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4916122A (en) 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en) 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
AU2526188A (en) 1987-09-22 1989-04-18 Regents Of The University Of California, The Liposomal nucleoside analogues for treating aids
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
ATE243039T1 (de) 1987-10-28 2003-07-15 Wellstat Therapeutics Corp Acyldeoxyribonukleosid-derivate und verwendungen davon
JP2675864B2 (ja) 1988-07-05 1997-11-12 キヤノン株式会社 被記録材及びこれを用いたインクジェット記録方法
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
JPH05507279A (ja) 1990-05-29 1993-10-21 ネクススター・ファーマシューティカルズ・インコーポレイテッド グリセロールジ―およびトリホスフェート誘導体の合成
JP3347723B2 (ja) 1990-06-13 2002-11-20 グラツィエル，アーノルド 含リンプロドラッグ
DK0543806T3 (da) 1990-07-12 1996-05-06 G Drill Ab Bjergboremaskine med hydraulisk drev i borehullet
ES2118069T3 (es) * 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
IT1246983B (it) 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IE920701A1 (en) 1991-03-06 1992-09-09 Wellcome Found Therapeutic nucleosides
US5220003A (en) * 1991-03-29 1993-06-15 The Regents Of The University Of California Process for the synthesis of 2',3'-dideoxynucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
WO1993000910A1 (en) 1991-07-12 1993-01-21 Vical, Inc. Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
CA2157902A1 (en) * 1993-03-10 1994-09-15 Christopher Douglas Valiant Black Tumour targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
JP3693357B2 (ja) 1993-04-09 2005-09-07 峯郎 実吉 逆転写酵素阻害剤
JPH08510236A (ja) 1993-05-12 1996-10-29 カール ワイ． ホステトラー 局所使用のためのアシクロビル誘導体
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
WO1995007086A1 (en) 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996011204A1 (de) * 1994-10-07 1996-04-18 Max-Delbrück-Centrum für Molekulare Medizin NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
WO1996040164A1 (en) * 1995-06-07 1996-12-19 Emory University Nucleosides with anti-hepatitis b virus activity
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
CA2322494A1 (en) 1998-03-11 1999-09-16 Annette M. Gero Novel nucleoside analogs and uses in treating disease
AU4716299A (en) 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CA2340156C (en) * 1998-08-10 2007-10-23 Novirio Pharmaceuticals Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6596700B2 (en) * 2000-05-26 2003-07-22 Idenix Pharmaceuticals Inc. Methods of treating hepatitis delta virus infection with β-L-2'-deoxy-nucleosides
US6787526B1 (en) * 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
EA007867B1 (ru) * 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения

Also Published As

Publication number Publication date
ES2255295T3 (es) 2006-06-16
NL300286I2 (nl) 2008-01-02
CA2340156A1 (en) 2000-02-24
CN1257912C (zh) 2006-05-31
EP1104436B1 (en) 2005-12-21
LU91348I9 (enrdf_load_stackoverflow) 2018-12-31
KR100691737B1 (ko) 2007-03-12
HK1097776A1 (en) 2007-07-06
US20060084624A1 (en) 2006-04-20
KR100634342B1 (ko) 2006-10-16
CN1478483A (zh) 2004-03-03
US20030225028A1 (en) 2003-12-04
BRPI9912896B1 (pt) 2016-08-09
RU2006147216A (ru) 2008-07-10
EP2415776A1 (en) 2012-02-08
ES2579903T3 (es) 2016-08-17
DE69929060T2 (de) 2006-08-31
US6395716B1 (en) 2002-05-28
ES2531928T3 (es) 2015-03-20
DK2415776T3 (en) 2016-07-04
KR100702230B1 (ko) 2007-04-03
CA2340156C (en) 2007-10-23
PT2415776T (pt) 2016-07-07
JP4294870B2 (ja) 2009-07-15
HK1111913A1 (en) 2008-08-22
KR100568035B1 (ko) 2006-04-07
SG132498A1 (en) 2007-06-28
HK1034083A1 (en) 2001-10-12
CN100482236C (zh) 2009-04-29
DE122007000062I1 (de) 2007-12-20
US7304043B2 (en) 2007-12-04
KR20010072392A (ko) 2001-07-31
ATE313550T1 (de) 2006-01-15
US20080064655A1 (en) 2008-03-13
AU5475799A (en) 2000-03-06
BR9912896A (pt) 2002-02-13
DE69929060D1 (de) 2006-01-26
DK1431304T3 (en) 2015-03-02
DK1104436T3 (da) 2006-04-03
CN100387237C (zh) 2008-05-14
CN1606983A (zh) 2005-04-20
LU91348I2 (fr) 2007-09-18
FR07C0046I1 (enrdf_load_stackoverflow) 2007-10-26
NL300286I1 (nl) 2007-10-01
KR20060035817A (ko) 2006-04-26
CY1116988T1 (el) 2017-04-05
KR20060038483A (ko) 2006-05-03
CY2007017I1 (el) 2009-11-04
JP2007269798A (ja) 2007-10-18
PT1431304E (pt) 2015-03-09
US6569837B1 (en) 2003-05-27
RU2424016C2 (ru) 2011-07-20
JP2002522552A (ja) 2002-07-23
WO2000009531A2 (en) 2000-02-24
EP1104436A2 (en) 2001-06-06
KR20050062664A (ko) 2005-06-23
MXPA01001507A (es) 2003-09-10
CY2007017I2 (el) 2009-11-04
EP2415776B1 (en) 2016-05-25
WO2000009531A3 (en) 2000-06-15
BRPI9912896B8 (pt) 2021-05-25
CN1320128A (zh) 2001-10-31

Similar Documents

Publication Publication Date Title
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
DE69731674D1 (de) Silencieux d'aspiration pour compresseur
MA25823A1 (fr) Compositions pour le traitement de l'eau.
DZ2396A1 (fr) Traitement de l'eau
EP1346724A4 (en) AGENT FOR TREATING HEPATITIS C
MA26822A1 (fr) Composes pour le traitement d'une ischemie.
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
FR2722681B1 (fr) Calecon pour homme
FR2771297B1 (fr) Sonde bicanaliculaire pour le traitement du larmoiement de l'oeil
FR2758465B1 (fr) Composition pour le traitement de l'amiante
FR2746658B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocephalie
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
FR2747398B1 (fr) Procede de traitement de surface d'une piece metallique
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
MA23837A1 (fr) Benzamides pour le traitement de degenerescenses neurologiques
FR2775199B1 (fr) Materiau composite pour le traitement d'effluents photographiques
EP0727620A3 (de) Dunstabzugshaube
FR2751637B1 (fr) Cellule d'electrocoagulation pour le traitement d'effluents
EP0981545A4 (en) TREATMENT OF OSTEOPOROSIS
MA25509A1 (fr) Composition destinee au traitement de l'hepatite c
FR2759290B1 (fr) Minalcipran pour le traitement de l'incontinence urinaire